Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05052268 · ClinicalTrials.gov registry record · Phase 1

XTX202 in Patients With Advanced Solid Tumors

A Phase 1 study of Advanced Solid Tumor, sponsored by Xilio Development.

Completed
Registry status
Phase 1
Development phase
95
Enrollment target
15
Study locations

NCT05052268: Completed Phase 1 study of Advanced Solid Tumor, sponsored by Xilio Development.

NCT05052268 is a Phase 1 study of Advanced Solid Tumor that has completed, run by Xilio Development. The registered enrollment target is 95 participants, below the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (51% lower). The trial reports 15 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05052268, a Phase 1 study of Advanced Solid Tumor, has completed, sponsored by Xilio Development.

COMPLETED
Registry status
Phase 1
Development phase
95 participants
Enrollment target
15
Study locations

Study Summary

A First-in-Human, Multicenter, Phase 1/2, Open-Label Study of XTX202 in Patients with Advanced Solid Tumors

Primary Outcome

All participants in Phase 1 Part 1A (Dose Escalation) who received at least 1 dose of XTX202 and experienced a DLT. DLTs were defined as the following: * Any treatment-related Grade ≥ 3 toxicity * Any Grade febrile neutropenia * The following nonhematologic exceptions: * Grade 3 nausea or vomiting lasting \< 3 days * Grade 3 fatigue lasting \< 7 days * Any treatment-related toxicity that resulted in a treatment delay of ≥ 7 days

Conditions Studied

Advanced Solid Tumor

Interventions

  • DRUG XTX202

Study Locations (15)

California

  • UC San Diego Moores Cancer Center - La Jolla
  • Norris Comprehensive Cancer Center - Los Angeles
  • University of California Los Angeles - Los Angeles
  • Hoag Memorial Hospital Presbyterian- Newport Beach - Newport Beach

New Jersey

  • Atlantic Health System/Morristown Medical Center - Morristown
  • Rutgers Cancer Institute of NJ - New Brunswick

District of Columbia

  • Georgetown University Medical Center - Washington D.C.

Florida

  • Moffitt Cancer Center - Tampa

Iowa

  • University of Iowa Hospitals and Clinics - Iowa City

Massachusetts

  • Massachusetts General Hospital - Boston

Minnesota

  • HealthPartners Cancer Center at Regions Hospital - Saint Paul

North Carolina

  • Carolina BioOncology Institute - Huntersville

Trial Details

FieldValue
Enrollment Target 95 participants
Start Date 2022-01-18
Est. Completion 2025-03-25
Phase Phase 1
Xilio Development

3 total trials

What the finished NCT05052268 record still lists

NCT05052268 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 95 participants, a relatively small participant target, below the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (51% lower).

The record links to 1 condition, with Advanced Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which XTX202 is the first listed.

NCT05052268 lists 15 locations in 11 states (California, New Jersey, District of Columbia).

Frequently Asked Questions

What is clinical trial NCT05052268 about?

NCT05052268 is a clinical study titled "XTX202 in Patients With Advanced Solid Tumors". A First-in-Human, Multicenter, Phase 1/2, Open-Label Study of XTX202 in Patients with Advanced Solid Tumors

What is the current status of trial NCT05052268?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 95 participants. The study started on 2022-01-18. Estimated completion is 2025-03-25.

What conditions does trial NCT05052268 study?

This clinical trial studies the following conditions: Advanced Solid Tumor.

What interventions are being tested in trial NCT05052268?

The interventions under investigation include: XTX202 (DRUG).

Who is sponsoring clinical trial NCT05052268?

This trial is sponsored by Xilio Development, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05052268 being conducted?

This trial has 15 study locations across California, District of Columbia, Florida, Iowa, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05052268's enrollment target sits among peer trials

95 120th of 189 higher than 69 of 189 other Advanced Solid Tumor trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Advanced Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03339128 · 95 participants · Phase 2

    Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children

  • NCT03509961 · 95 participants · Phase 2

    The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL

  • NCT03694756 · 95 participants · NA

    TMEM-MRI: A Pilot Feasibility Study of MRI for Imaging of TMEM in Patients With Operable Breast Cancer

  • NCT04206215 · 95 participants · NA

    Noninvasive Brain Stimulation for Treating Carpal Tunnel Syndrome

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT05052268, the US trial registry maintained by the National Library of Medicine. NCT05052268 (small enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.